98488-10-9

Usage

Uses

Used in Pharmaceutical Industry:
2,5-DIMETHYLPYRAZOLO(1,5-A)PYRIMIDIN-7-ONE is used as a building block for the synthesis of various biologically active compounds, contributing to the development of new drugs with potential therapeutic applications.
Used in Cancer Treatment:
In the field of oncology, 2,5-DIMETHYLPYRAZOLO(1,5-A)PYRIMIDIN-7-ONE is used as a potential drug candidate for the treatment of cancer, due to its ability to target and affect biological processes involved in tumor growth and progression.
Used in Inflammation Treatment:
2,5-DIMETHYLPYRAZOLO(1,5-A)PYRIMIDIN-7-ONE is also considered in the development of treatments for inflammation, given its potential to modulate inflammatory responses and alleviate symptoms associated with inflammatory conditions.
Used in Antimicrobial Applications:
2,5-DIMETHYLPYRAZOLO(1,5-A)PYRIMIDIN-7-ONE is used as an antimicrobial agent, leveraging its properties to combat bacterial infections and contributing to the development of new antibiotics.
Used in Antiviral Applications:
In the context of antiviral research, 2,5-DIMETHYLPYRAZOLO(1,5-A)PYRIMIDIN-7-ONE is used to explore its potential to inhibit viral replication and activity, offering a new avenue for the treatment of viral diseases.
Used in Anti-fungal Applications:
2,5-DIMETHYLPYRAZOLO(1,5-A)PYRIMIDIN-7-ONE is utilized in antifungal applications to study its efficacy against fungal infections, with the aim of developing new antifungal agents.
Used in Agrochemicals:
Beyond medicine, 2,5-DIMETHYLPYRAZOLO(1,5-A)PYRIMIDIN-7-ONE also has potential applications in agrochemicals, where it may be employed to develop new pesticides or fungicides to protect crops from various pathogens.

InChI:InChI=1/C8H9N3O/c1-5-4-8(12)11-7(9-5)3-6(2)10-11/h3-4,9H,1-2H3

Upstream product

• 31230-17-8 3-methyl-5-aminopyrazole 
• 141-97-9 ethyl acetoacetate 
• 31230-17-8 3-amino-5-methylpyrazole 
• 105-45-3 acetoacetic acid methyl ester 

Downstream Products

• 1031639-13-0 C₁₄H₁₄N₄ 
• 136549-13-8 7-chloro-2,5-dimethyl-pyrazolo[1,5-a]pyrimidine 

Relevant academic research and scientific papers

Comparative study between the anti-P. falciparum activity of triazolopyrimidine, pyrazolopyrimidine and quinoline derivatives and the identification of new PfDHODH inhibitors

In this work, we designed and synthesized 35 new triazolopyrimidine, pyrazolopyrimidine and quinoline derivatives as P. falciparum inhibitors (3D7 strain). Thirty compounds exhibited anti-P. falciparum activity, with IC50 values ranging from 0.030 to 9.1 μM. The [1,2,4]triazolo[1,5-a]pyrimidine derivatives were more potent than the pyrazolo[1,5-a]pyrimidine and quinoline analogues. Compounds 20, 21, 23 and 24 were the most potent inhibitors, with IC50 values in the range of 0.030–0.086 μM and were equipotent to chloroquine. In addition, the compounds were selective, showing no cytotoxic activity against the human hepatoma cell line HepG2. All [1,2,4]triazolo[1,5-a]pyrimidine derivatives inhibited PfDHODH activity in the low micromolar to low nanomolar range (IC50 values of 0.08–1.3 μM) and did not show significant inhibition against the HsDHODH homologue (0–30% at 50 μM). Molecular docking studies indicated the binding mode of [1,2,4]triazolo[1,5-a]pyrimidine derivatives to PfDHODH, and the highest interaction affinities for the PfDHODH enzyme were in agreement with the in vitro experimental evaluation. Thus, the most active compounds against P. falciparum parasites 20 (R = CF3, R1 = F; IC50 = 0.086 μM), 21 (R = CF3; R1 = CH3; IC50 = 0.032 μM), 23, (R = CF3, R1 = CF3; IC50 = 0.030 μM) and 24 (R = CF3, 2-naphthyl; IC50 = 0.050 μM) and the most active inhibitor against PfDHODH 19 (R = CF3, R1 = Cl; IC50 = 0.08 μM - PfDHODH) stood out as new lead compounds for antimalarial drug discovery. Their potent in vitro activity against P. falciparum and the selective inhibition of the PfDHODH enzyme strongly suggest that this is the mechanism of action underlying this series of new [1,2,4]triazolo[1,5-a]pyrimidine derivatives.

Evaluation of 7-arylaminopyrazolo[1,5-a]pyrimidines as anti-Plasmodium falciparum, antimalarial, and Pf-dihydroorotate dehydrogenase inhibitors

Malaria remains one of the most serious global infectious diseases. An important target for antimalarial chemotherapy is the enzyme dihydroorotate dehydrogenase from Plasmodium falciparum (PfDHODH), which is responsible for the conversion of dihydroorotat

Aminopyrazolo[1,5-a]pyrimidines as potential inhibitors of Mycobacterium tuberculosis: Structure activity relationships and ADME characterization

Whole-cell high-throughput screening of a diverse SoftFocus library against Mycobacterium tuberculosis (Mtb) generated a novel aminopyrazolo[1,5-a]pyrimidine hit series. The synthesis and structure activity relationship studies identified compounds with p

THIOPHENE PYRAZOLOPYRIMIDINE COMPOUNDS

The present invention relates to compounds of Formula (I), pharmaceutical compositions thereof, and the use of such compounds as corticotropin releasing factor 1 (CRF1) receptor antagonists in the treatment of psychiatric and neuroendocrine disorders, neurological diseases, and metabolic syndrome.

THIAZOLE PYRAZOLOPYRIMIDINES AS CRF1 RECEPTOR ANTAGONISTS

The present invention relates to compounds of Formula (I), pharmaceutical compositions thereof, and use thereof as corticotropin releasing factor 1 (CRF1) receptor antagonists in the treatment of psychiatric and neuroendocrine disorders, neurological dise

Condensation of 5-aminopyrazoles unsubstituted in position 1 with β-keto esters

Condensation of β-keto esters with 5-aminopyrazoles unsubstituted in position 1 gives 7-oxopyrazolo[1, 5-a]pyrimidines.